Treatment of atrial fibrillation
Individualising atrial fibrillation (AF) treatment helps you optimise symptomatic outcomes and reduce stroke risk.
This part of the Learning Zone introduces the various AF treatments. Up to 50% of patients with recent onset AF spontaneously convert to sinus rhythm.20 The remainder need one or more of the treatments covered in this section. The ESC/EHRA guidelines stress the importance of counselling patients starting AF management to prevent unrealistic expectations and to optimise QoL.5
Broadly, patients and clinicians need to decide between rhythm and rate control. Currently, no trial data compares rhythm and rate control as an initial AF treatment. However, consensus guidelines suggest restoring sinus rhythm, which may control AF arising from potentially reversible causes or in those patients experiencing an isolated episode.6
If AF recurs, patients who seem especially suitable for rhythm control include:6
- those who showed a symptomatic improvement during normal sinus rhythm
- young people
- those with AF without underlying heart disease
- patients with substantial symptoms despite control of ventricular rate
Anticoagulation is an important aspect of management to reduce the risk of ischaemic stroke in all AF patients.5,37
Comorbidities and risk factors
Several comorbidities and risk factors contribute to AF and the risk of stroke.
Several modifiable comorbidities and risk factors seem to promote AF development and maintain the arrhythmia (Figure 13).6
Heart rate control
Heart rate control is only suitable for some AF patients; this section suggests when heart rate control may be appropriate.
Antiarrhythmic drugs (AADs) are not routinely used for asymptomatic AF or by people with permanent AF who did not undergo rhythm control.5,6 AADs also have important contraindications and cause dose-limiting adverse events.
Nevertheless, AADs can re-establish normal heart rate and left ventricular function in AF patients with cardiomyopathy and may increase the likelihood of successful electrical cardioversion if initial attempts were unsuccessful.6
Electrical cardioversion is a cornerstone of AF care, but patients still need effective anticoagulation and pretreatment.
Initially, many AF patients require ventricular rate control to reduce the risk that tachycardia will cause cardiomyopathy and CHF, even if the patient does not show left ventricular systolic dysfunction.6 Nevertheless, 20–30% of AF patients show left ventricular dysfunction.5
Find out which patients may be more suitable for pharmacological than electrical cardioversion.
In recent onset AF (Figure 15), the ESC/EHRA guidelines suggest rhythm control to improve symptoms. The guidelines also prefer rhythm to rate control in pre-excited AF (ventricles depolarise prematurely) and AF during pregnancy.
Invasive treatments offer an option when drugs are contraindicated, poorly tolerated or not fully effective.
Invasive treatments offer an option when drugs are contraindicated, poorly tolerated or not fully effective. The ESC/EHRA guidelines, for instance, suggest considering atrioventricular node ablation to control heart rate in patients unresponsive or intolerant to intensive rate and rhythm control therapy.
Introduction to anticoagulation
Learn why most AF patients, other than those at very low stroke risk, should receive anticoagulants.
The coagulation cascade (Figure 19) refers to a series of enzymatic reactions that begins when damage to the endothelium of a blood vessel exposes circulating platelets to collagen in the wall and plasma factor VII/VIIa to extravascular tissue factor.
References for Anticoagulation Therapy for Stroke Prevention
1. Wyndham CR. Atrial fibrillation: The most common arrhythmia. Tex Hear Inst J. 2000;27(3):257–267.
2. Zoni-Berisso M, Lercari F, Carazza T, Domenicucci S. Epidemiology of atrial fibrillation: European perspective. Clin Epidemiol. 2014;6:213–220.
3. Béjot Y, Bailly H, Durier J, Giroud M. Epidemiology of stroke in Europe and trends for the 21st century. Press Méd. 2016;45(12, Part 2):e391–e398.
4. Contractor T, Khasnis A. Left atrial appendage closure in atrial fibrillation: A world without anticoagulation? Cardiol Res Pr. 2011;2011:752808.
5. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Hear J. 2016;37(38):2893–2962.
6. Rogers PA, Bernard ML, Madias C, Thihalolipavan S, Mark Estes NA, Morin DP. Current evidence-based understanding of the epidemiology, prevention, and treatment of atrial fibrillation. Curr Probl Cardiol. 2018;43(6):241–283.
7. Hankey GJ. Stroke. Lancet. 2017;389(10069):641–654.
8. Amarenco P, Bogousslavsky J, Caplan LR, Donnan GA, Hennerici MG. Classification of stroke subtypes. Cerebrovasc Dis. 2009;27(5):493–501.
9. Hopewell C. J, Clarke R. Emerging risk factors for stroke. Stroke. 2016;47(6):1673–1678.
10. Heiss WD. The ischemic penumbra: Correlates in imaging and implications for treatment of ischemic stroke. Cerebrovasc Dis. 2011;32(4):307–320.
11. Bhatt H V, Fischer GW. Atrial fibrillation: Pathophysiology and therapeutic options. J Cardiothor Vasc An. 2015;29(5):1333–1340.
12. Pistoia F, Sacco S, Tiseo C, Degan D, Ornello R, Carolei A. The epidemiology of atrial fibrillation and stroke. Cardiol Clin. 2016;34(2):255–268.
13. Reiffel JA, Verma A, Kowey PR, Halperin JL, Gersh BJ, Wachter R, et al. Incidence of previously undiagnosed atrial fibrillation using insertable cardiac monitors in a high-risk population: The REVEAL AF Study. JAMA Cardiol. 2017;2(10):1120–1127.
14. Heeringa J, van der Kuip DAM, Hofman A, Kors JA, van Herpen G, Stricker BHC, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: The Rotterdam study. Eur Hear J. 2006;27(8):949–953.
15. Pérez-Gómez F, Alegría E, Berjón J, Iriarte JA, Zumalde J, Salvador A, et al. Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: a randomized multicenter study. J Am Coll Cardiol. 2004;44(8):1557–66.
16. Wang TY, Robinson LA, Ou F-S, Roe MT, Ohman EM, Gibler WB, et al. Discharge antithrombotic strategies among patients with acute coronary syndrome previously on warfarin anticoagulation: Physician practice in the CRUSADE registry. Am Heart J. 2008;155(2):361–368.
17. Kralev S, Schneider K, Lang S, Süselbeck T, Borggrefe M. Incidence and severity of coronary artery disease in patients with atrial fibrillation undergoing first-time coronary angiography. PLoS One. 2011;6(9):e24964.
18. Mehran R, Kalkman DN, Angiolillo DJ. Atrial fibrillation, with ACS and PCI: walking a tightrope. Eur Heart J. 2019;40(19):1563–1566.
19. Dilaveris PE, Kennedy HL. Silent atrial fibrillation: Epidemiology, diagnosis, and clinical impact. Clin Cardiol. 2017;40(6):413–418.
20. Lip GYH, Tse HF, Lane DA. Atrial fibrillation. Lancet. 2012;379(9816):648–661.
21. Kamel H, Okin PM, Elkind MS V, Iadecola C. Atrial fibrillation and mechanisms of stroke: Time for a new model. Stroke. 2016;47(3):895–900.
22. Friberg J, Scharling H, Gadsbøll N, Truelsen T, Jensen GB. Comparison of the impact of atrial fibrillation on the risk of stroke and cardiovascular death in women versus men (The Copenhagen City Heart Study). Am J Cardiol. 2004;94(7):889–894.
23. Hayden T. D, Hannon N, Callaly E, Ní Chróinín D, Horgan G, Kyne L, et al. Rates and determinants of 5-year outcomes after atrial fibrillation–related stroke. Stroke. 2015;46(12):3488–3493.
24. Hahne K, Mönnig G, Samol A. Atrial fibrillation and silent stroke: Links, risks, and challenges. Vasc Heal Risk Manag. 2016;12:65–74.
25. Fatkin D, Santiago CF, Huttner IG, Lubitz SA, Ellinor PT. Genetics of atrial fibrillation: State of the art in 2017. Hear Lung Circ. 2017;26(9):894–901.
26. Gutierrez A, Chung MK. Genomics of atrial fibrillation. Curr Cardiol Rep. 2016;18(6):55.
27. Kim J-B. Channelopathies. Korean J Pediatr. 2014;57(1):1–18.
28. Herraiz-Martínez A, Llach A, Tarifa C, Gandía J, Jiménez-Sabado V, Lozano-Velasco E, et al. The 4q25 variant rs13143308T links risk of atrial fibrillation to defective calcium homoeostasis. Cardiovasc Res. 2018;115(3):578–589.
29. Veenhuyzen GD, Simpson CS, Abdollah H. Atrial fibrillation. CMAJ. 2004;171(7):755–760.
30. Roderick HL, Berridge MJ, Bootman MD. Calcium-induced calcium release. Curr Biol. 2003;13(11):R425.
31. Strollo PJ, Rogers RM. Obstructive sleep apnea. N Engl J Med. 1996;334(2):99–104.
32. Gutierrez C, Blanchard DG. Diagnosis and treatment of atrial fibrillation. Am Fam Physician. 2016;94(6):442–452.
33. Safavi-Naeini P, Rasekh A. Update on atrial fibrillation. Tex Hear I J. 2016;43(5):412–414.
34. Amerena J, Ridley D. An update on anticoagulation in atrial fibrillation. Hear Lung Circ. 2017;26(9):911–917.
35. Randolph TC, Simon DN, Thomas L, Allen LA, Fonarow GC, Gersh BJ, et al. Patient factors associated with quality of life in atrial fibrillation. Am Hear J. 2016;182:135–143.
36. Johnsen SP, Dalby LW, Täckström T, Olsen J, Fraschke A. Cost of illness of atrial fibrillation: A nationwide study of societal impact. BMC Heal Serv Res. 2017;17(1):714.
37. January T. C, Wann LS, Calkins H, Chen Lin Y, Cigarroa Joaquin E, Cleveland Joseph C, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart R. Circulation. 2019;140(2):e125–e151.
38. Wollert KC, Kempf T, Wallentin L. Growth differentiation factor 15 as a biomarker in cardiovascular disease. 2017;63(1):140–151.
39. Mackman N, Tilley Rachel E, Key Nigel S. Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. Arter Thromb Vasc Biol. 2007;27(8):1687–1693.
40. Saraf K, Morris P, Garg P, Sheridan P, Storey R. Non-vitamin K antagonist oral anticoagulants (NOACs): Clinical evidence and therapeutic considerations. Postgr Med J. 2014;90(1067):520–528.
41. Pirmohamed M. Warfarin: almost 60 years old and still causing problems. Br J Clin Pharmacol. 2006;62(5):509–511.
42. Hoffman M, Monroe DM. Impact of non-vitamin K antagonist oral anticoagulants from a basic science perspective. Arter Thromb Vasc Biol. 2017;37(10):1812–1818.
43. Almutairi AR, Zhou L, Gellad WF, Lee JK, Slack MK, Martin JR, et al. Effectiveness and safety of non–vitamin k antagonist oral anticoagulants for atrial fibrillation and venous thromboembolism: A systematic review and meta-analyses. Clin Ther. 2017;39(7):1456-1478.e36.
44. Kane S. NOAC, DOAC, or TSOAC: What should we call novel oral anticoagulants? Pharm Times. 2016;Available at https://www.pharmacytimes.com/contrib.
45. Lip GYH, Agnelli G. Edoxaban: A focused review of its clinical pharmacology. Eur Hear J. 2014;35(28):1844–1855.
46. Pan K-L, Singer DE, Ovbiagele B, Wu Y-L, Ahmed MA, Lee M. Effects of non-vitamin k antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and valvular heart disease: A systematic review and meta-analysis. J Am Hear Assoc. 2017;6(7):e005835.
47. Kovacs RJ, Flaker GC, Saxonhouse SJ, Doherty JU, Birtcher KK, Cuker A, et al. Practical management of anticoagulation in patients with atrial fibrillation. J Am Coll Cardiol. 2015;65(13):1340–1360.
48. Renda G, Ricci F, Giugliano RP, De Caterina R. Non–vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and valvular heart disease. J Am Coll Cardiol. 2017;69(11):1363–1371.
49. Capodanno D, Alfonso F, Levine GN, Valgimigli M, Angiolillo DJ. ACC/AHA versus ESC guidelines on dual antiplatelet therapy. J Am Coll Cardiol. 2018;72(23):2915–2931.
50. Capodanno D, Angiolillo DJ. Management of antiplatelet and anticoagulant therapy in patients with atrial fibrillation in the setting of Acute Coronary Syndromes or Percutaneous Coronary Interventions. Circ Cardiovasc Interv. 2014;7(1):113–124.
51. Neumann F-J, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, et al. [2018 ESC/EACTS Guidelines on myocardial revascularization. The Task Force on myocardial revascularization of the European Society of Cardiology (ESC) and European Association for Cardio-Thoracic Surgery (EACTS)]. G Ital Cardiol (Rome).20(7):1–61.
52. Angiolillo DJ, Goodman SG, Bhatt DL, Eikelboom JW, Price MJ, Moliterno DJ, et al. Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing Percutaneous Coronary Intervention. Circulation. 2018;138(5):527–536.
53. Oldgren J, Steg PG, Hohnloser SH, Lip GYH, Kimura T, Nordaby M, et al. Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial. Eur Heart J. 2019;40(19):1553–1562.
54. Vranckx P, Lewalter T, Valgimigli M, Tijssen JG, Reimitz P-E, Eckardt L, et al. Evaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention (PCI) with stent placement: Rationale and design of the ENTRUST-AF PCI trial. Am Heart J. 2018;196:105–112.
55. Lopes RD, Heizer G, Aronson R, Vora AN, Massaro T, Mehran R, et al. Antithrombotic therapy after Acute Coronary Syndrome or PCI in atrial fibrillation. N Engl J Med. 2019;380(16):1509–1524.
56. Lopes RD, Hong H, Harskamp RE, Bhatt DL, Mehran R, Cannon CP, et al. Safety and efficacy of antithrombotic strategies in patients with atrial fibrillation undergoing percutaneous coronary intervention. JAMA Cardiol. 2019. doi:10.1001/jamacardio.2019.1880.
Developed by EPG Health for Medthority. This content has been developed independently of the sponsors who have had no editorial input into the content. Medthority received educational funding from the sponsor in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.